CareDx (CDNA) director Michael Goldberg receives 1,492-share equity grant

Rhea-AI Filing Summary

CareDx, Inc. director Michael Goldberg reported receiving an automatic quarterly grant of common stock as part of his non-employee director compensation. On January 6, 2026, he was awarded 1,492 shares of CareDx common stock at a reported price of $0 per share, reflecting equity paid in lieu of cash fees under the company’s Outside Director Compensation Policy. Following this grant, he beneficially owned 157,461 shares of CareDx common stock held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goldberg Michael

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		1,492(1)	A	$0	157,461	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy.

	/s/ Jeffrey Adam Novack, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CareDx (CDNA) report for Michael Goldberg?

CareDx director Michael Goldberg reported receiving an automatic quarterly grant of 1,492 shares of common stock on January 6, 2026 as director compensation.

How many CareDx (CDNA) shares does Michael Goldberg own after this Form 4?

After the reported transaction, Michael Goldberg beneficially owned 157,461 shares of CareDx common stock, held directly.

Was the CareDx (CDNA) director transaction a purchase, sale, or grant?

The Form 4 shows a transaction coded "A", indicating an acquisition of shares through an automatic stock grant, not an open-market purchase or sale.

What price per share is reported for Michael Goldberg’s CareDx (CDNA) stock grant?

The Form 4 reports a price of $0 per share for the 1,492 shares, consistent with an equity award granted as compensation rather than a cash purchase.

Why did CareDx (CDNA) grant shares to its director instead of cash?

The footnote explains the 1,492-share grant represents an automatic quarterly award in lieu of cash under CareDx’s Outside Director Compensation Policy for non-employee directors.

Is Michael Goldberg’s CareDx (CDNA) stock grant held directly or indirectly?

The filing lists the 157,461 shares after the transaction as held with ownership form Direct (D), meaning they are reported as directly owned by Michael Goldberg.